Biocon gets CDSCO nod for generic diabetes medication

Biocon has secured Indian regulatory approval for its generic Liraglutide drug substance and product, a version of Victoza, for treating Type 2 Diabetes in adults and children over 10. CEO Siddharth Mittal highlighted the importance of this vertically integrated GLP-1 drug in expanding access for diabetes patients in India, where cases are rapidly increasing.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/IeX23DK
via IFTTT